After so much effort to bring immunotherapy into HR+/HER2− mBC, KEYNOTE-B49 raises a hard question: is this worth it? A 0.7-month median PFS gain and no demonstrated OS benefit. We

Elvina Almuradova· @Dr_ElvinaA · X·2026-10-24 15:05· 22 hours agoScore70

Body

After so much effort to bring immunotherapy into HR+/HER2− mBC, KEYNOTE-B49 raises a hard question: is this worth it? A 0.7-month median PFS gain and no demonstrated OS benefit. We need more meaningful returns for our patients. #ESMO26 @myESMO @Larvol @OncoAlert

104 views · 3 likes · 3 reposts · 0 replies

Conference abstracts

LBA51matched by Proffered paper 2: Breast cancer, early and advanced stage

Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)

https://esmocongress.esmo.org

Source: Elvina Almuradova · x.com